Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Virtual Plenary: November 2021

ESMO-Virtual-Plenaries-November-2021-1000x250
Start date
19 Nov 2021
End date
20 Nov 2021
ESMO-Asia-Virtual-Oncology-Week-1000x1000

This ESMO Virtual Plenary is part of the ESMO Asia Virtual Oncology Week 2021 (#ESMOasiaweek21), taking place on 17-23 November, and presenting the most important innovations in cancer research and care in 2021, highlighting Asian studies with a strong impact on the science and practice of oncology. Participation is free of charge.

Register via #ESMOAsiaweek21

Friday, 19 November 2021

12:00-13:15 CET / 19:00-20:15 SGT

Welcome and introduction, Scientific background and context

Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Osaka, Japan

ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

Shun Lu, Shanghai Chest Hospital, Shanghai, China

Critical analysis and perspectives

Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Expert Insights Panel Discussion / Q&A

Faculty and online audience

  • Chair: Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Osaka, Japan
  • Shun Lu, Shanghai Chest Hospital, Shanghai, China
  • Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
  • Benjamin Besse, Gustave Roussy, Villejuif, France
  • Daniel Tan, NCCS - National Cancer Centre Singapore, Singapore

Saturday, 20 November 2021

12:00-13:15 CET / 19:00-20:15 SGT

Welcome and introduction, Scientific background and context

John Lubel, Monash University, Melbourne, Australia

Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Robin Kelley, UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Critical analysis and perspectives

Ian Chau, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK

Expert Insights Panel Discussion / Q&A

Faculty and online audience

  • Chair: John Lubel, Monash University, Melbourne, Australia
  • Robin Kelley, UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
  • Ian Chau, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK
  • Su Pin Choo, NCCS - National Cancer Centre Singapore, Singapore
  • Chih-Hung Hsu, NTUH - National Taiwan University Hospital, Taipei, Taiwan

The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.

The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings